SEARCH

SEARCH BY CITATION

References

  • 1
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 58593.
  • 2
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159: 44553.
  • 3
    Heijboer H, Brandjes DP, Buller HR, Sturk A, Ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 15126.
  • 4
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000; 160: 80915.
  • 5
    Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis. In. Bloom, AL Forbes, CD Thomas, DP Tuddenham, EGD, eds. Haemostasis and Thrombosis, 3. Edinburgh: Churchill Livingstone, 1994: 132733.
  • 6
    Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 15036.
  • 7
    Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 51722.
  • 8
    Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 177782.
  • 9
    Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698703.
  • 10
    Margaglione M, Brancaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaccone L et al. Increased risk for venous thrombosis in carriers of the prothrombin G[RIGHTWARDS ARROW]A20210 gene variant. Ann Intern Med 1998; 129: 8993.
  • 11
    Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 9127.
  • 12
    Hooper WC, Dilley A, Ribeiro MJ, Benson J, Austin H, Silva V et al. A racial difference in the prevalence of the Arg506[RIGHTWARDS ARROW]Gln mutation. Thromb Res 1996; 81: 57781.
  • 13
    Dilley A, Austin H, Hooper WC, El-Jamil M, Whitsett C, Wenger NK et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 1998; 132: 4525.
  • 14
    White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 73740.
  • 15
    Benson JM, Ellingsen D, El-Jamil M, Jenkins M, Miller CH, Dilley A et al. Factor V Leiden and factor V, R2 allele: high–throughput analysis and association with venous thromboembolism. Thromb Haemost 2001; 86: 118892.
  • 16
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 71948.
  • 17
    Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons, Inc., 1989.
  • 18
    Martin D, Austin H. An efficient program for computing conditional maximum likelihood estimates and exact confidence limits for a common odds ratio. Epidemiology 1991; 2: 35962.
  • 19
    Piegorsch WW, Weinberg CR, Taylor JA. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case–control studies. Stat Med 1994; 13: 15362.
  • 20
    Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene–environment interaction: case – control studies with no controls. Am J Epidemiol 1996; 144: 20713.
  • 21
    Weir B. Genetic Data Analysis II. Sunderland: MA. Sinauer Associates, Inc., 1996.
  • 22
    Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, De Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 647.
  • 23
    Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH et al. The risk of recurrent venous thromboembolism in patients with an Arg506[RIGHTWARDS ARROW]Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399403.
  • 24
    Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 1113.
  • 25
    Kluijtmans LA, Den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79: 2548.
  • 26
    Margaglione M, D'Andrea G, D'Addedda M, Giuliani N, Cappucci G, Iannaccone L et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998; 79: 90711.
  • 27
    Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C et al. Coexistence of hereditary homocyteinuria and factor V Leiden – effect on thrombosis. N Engl J Med 1996; 334: 7638.
  • 28
    Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e) inemia, factor V Leiden, and the risk of future venous thromboemoblism. Circulation 1997; 95: 177782.
  • 29
    Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti M, Bignell M et al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (Factor V. Q506). Arterioscler Thromb Vasc Biol 1997; 17: 16626.
  • 30
    Brown K, Luddington R, Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol 1998; 103: 424.
  • 31
    Alhenc-Gelas M, Arnaud E, Nicaud V, Aubry M, Fiessinger J, Aiach M et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999; 81: 50610.
  • 32
    De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 8016.
  • 33
    Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, DeStefano V, Cumming T et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Thromb Haemost 2001; 86: 80916.